$1.67
-0.16 (-8.74%)
Open$1.79
Previous Close$1.83
Day High$1.79
Day Low$1.65
52W High$10.00
52W Low$1.46
Volume—
Avg Volume349.1K
Market Cap20.41M
P/E Ratio—
EPS$-3.21
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+2,060.5% upside
Current
$1.67
$1.67
Target
$36.08
$36.08
$23.71
$36.08 avg
$52.26
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 6.70M | 8.74M | 8.70M |
| Net Income | -45,091,188 | -76,794 | -87,592 |
| Profit Margin | -673.1% | -0.9% | -1.0% |
| EBITDA | -47,313,695 | -105,264 | -93,337 |
| Free Cash Flow | — | -51,137 | -57,721 |
| Rev Growth | — | +8.7% | -7.3% |
| Debt/Equity | — | 0.73 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |